Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III SOM230 LAR dosing in Cushing's disease
CTR20130866Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pasireotide LAR in Corticotropin adenoma (ACTHoma), sponsored by Novartis. Started Jan 2015; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on CTR20130866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130866.